It turns out that the administration of the Sinopharm vaccine as a booster can be well-tolerated
Jakarta (ANTARA) - State-owned pharmaceutical firm PT Kimia Farma Tbk notified that the adult populace could receive Sinopharm as a homologous booster vaccine since it has obtained the Emergency Use Authorization (EUA).

Thus, people over 18 years of age and having received the complete primary dosage of the Sinopharm vaccine at least six months before can be administered the same vaccine as a booster.

"The provision of the Sinopharm booster vaccine aims to expedite the government's mass vaccination program," Corporate Secretary of the enterprise Ganti Winarno noted in a statement here on Saturday.

Winarno remarked that before issuing the EUA, the National Agency of Drug and Food Control (BPOM) had evaluated the efficacy and safety of the utilization of the Sinopharm vaccine.

"It turns out that the administration of the Sinopharm vaccine as a booster can be well-tolerated," he noted.

This is since the BPOM's assessment found that the frequency, type, and severity of adverse events following immunization (AEFI) after the Sinopharm booster administration were lower than those of the administration of the primary dose.

AEFI often experienced only included local reactions, such as pain, swelling, and redness at the injection site, as well as systemic reactions, such as headache, fatigue, and muscle ache, with a severity level of I to II.

Furthermore, regarding the measurement of the increase in humoral immunity response, the surge in neutralizing antibodies and anti-IgG antibodies were recorded at 8.4 times and eight times respectively.

Winarno remarked that individuals as well as legal institutions or business entities looking to get Sinopharm booster vaccinations for themselves or their employees have been able to register through the or contact the WhatsApp number of PT Bio Farma -- PT Kimia Farma’s parent company -- at 08112060888.

Earlier, the BPOM had issued EUA for Sinovac, Pfizer, AstraZeneca, Moderna, and Zifivax as booster vaccine for adults over 18 years of age.

According to the official site of the COVID-19 Task Force, as of February 11, 2022, the total number of booster vaccination recipients in Indonesia had reached 6,623,413 people.

Related news: BPOM issues EUA for Sinopharm as booster shot
Related news: COVID-19: 6.3 million Indonesians receive booster shots
Related news: Merah Putih vaccine to be used as booster, child vaccine: Minister

Translator: Citro Atmoko, Uyu Liman
Editor: Sri Haryati
Copyright © ANTARA 2022